http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2435763-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2007-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ea7bed61eefa1cbf7fb05ecef84c11b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b1f75f72c06b2a4255022940297c35e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69635bb2a20808f91f83bc16e916e2aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e52b1a83c5266dc968882e0e7eec17da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d61308b37b04ea9acf70c9b1db9863b |
| publicationDate | 2011-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2435763-C2 |
| titleOfInvention | Human protein tyrosine phosphatase inhibitors and application methods thereof |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to compounds of general formula where R denotes a thiazolyl group of formula R 2 and R 3 are selected from: hydrogen, C 1 -C 3 linear alkyl; R 4 is selected from: C 1 -C 3 linear or C 3 cyclic alkyl, phenyl and thiophenyl; Z denotes a group of formula: -(L) n -R 1 ; R 1 is selected from: i) C 1 -C 3 linear or branched alkyl, optionally substituted with C 1 -C 4 alkoxycarbonyl, halogen; ii) substituted phenyl or substituted with one or two substitutes selected from halogen, methoxy- or hydroxy group, C 1 -C 4 alkoxycarbonyl; iii) dioxopiperazinyl and 2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl, substituted with C 1 -C 3 alkyl; or iv) heteroaryl rings containing 5-10 atoms selected from thiazole, triazole, 1H-imidazole, thiadiazole, oxazole, isoxazole, oxadiazole, benzodioxole, benzo(1,4)dioxepanyl, pyridine, pyrimidine, 1H-indole, 2,3-dihydrobenzo[b][1,4]dioxynil, which can be substituted with oine or two substitutes selected from: a) hydroxy; b) C 1 -C 3 alkyl (which can be substituted with one more two substitutes selected from: ) phenyl; ii) C 1 -C 4 alkoxycarbonyl; iii) naphthalenyl; iv) 2-methylthiazolyl) ; c) NHC(O)C 1 -C 3 alkyl; d) C 1 -C 4 alkoxycarbonyl; e) 1 -(tert-butoxycarbonyl)-2-phenylethyl; f) methoxybenzyl; g) phenyl which can be substuted with C 1 -C 4 alkoxy, halogen, methoxycarbonyl or >NHC(O)CH 3 ; h) (methoxy-2-oxoethyl)carbamoyl; L denotes a group selected from: i) C(O)NH[C(R 5a R 5b )] w -; ii) -C(O)[C(R 6a R 6b )] x -; iii) -C(O)[C(R 7a R 7b )] y C(O)-; iv) -SO 2 [C(R 8a R 8b )] z -; R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a and R 8b , each independently denotes: i) hydrogen; ii) C 1 -C 3 linear alkyl which can be substituted with 1 or 2 halogen atoms; iii) phenyl which can be substituted with 1-2 substitutes selected from halogen and lower alkoxy; iv) heteroaryl rings selected from imidazolyl, imidazolyl substituted with methyl, benzo(1,4)oxazinyl, oxadiazolyl substituted with methyl; index n equals 0 or 1; indices w, x, y and z are each independently equal to a number from 1 to 3. The invention also relates to pharmaceutically acceptable salts of compounds of formula (I) and use of compounds of formula (I) to prepare a medicinal agent for treating protein tyrosine phosphatase beta-mediated conditions. n EFFECT: obtaining compounds of formula (I) as human protein tyrosine phosphatase beta (HPTP-β) inhibitors. n 15 cl, 17 dwg, 13 tbl, 16 ex |
| priorityDate | 2006-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 655.